Nothing said here yet.
to join the conversation.
| Gonzales AnitaVP and CAO | Sell | 84 | $13.1K | Thu, Oct 1 |
| Krakowiak MaxwellPlease See Remarks | Sell | 1,631 | $235.7K | Mon, Sep 21 |
| Vohra Tajinder SPlease See Remarks | Sell | 7,330 | $1.0M | Wed, Sep 16 |
| Gilbert Cisneros | Sell | $32.5K | Wed, Sep 9 | Fri, Oct 9 |
| Gilbert Cisneros | Sell | $8.0K | Fri, Sep 4 | Fri, Oct 9 |
| Gilbert Cisneros | Sell | $8.0K | Thu, Sep 3 | Fri, Oct 9 |
| Gilbert Cisneros | Buy | $32.5K | Mon, May 4 | Fri, Jun 5 |
| Gilbert Cisneros | Buy | $8.0K | Fri, May 1 | Thu, May 7 |
Revvity has logged strong share gains in recent years, which naturally puts the spotlight on whether the current price lines up with the cash the business is expected to generate.
RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.
Revvity (RVTY) is back on investor calendars after announcing third quarter 2026 results are due on 3 November, with earnings per share expected to be higher and fresh conference appearances scheduled soon after.
Revvity has delivered a strong share price run over the past year, and the key issue now is whether that market enthusiasm lines up with the cash the business can realistically generate.